It’s been said that biotechs are among the riskiest of initial public offerings due to the dualistic nature of their meds: they either succeed or they flop. There’s usually no… Read more »
Steve’s Take: After a perfectly miserable 2016, IPO issuers have been praying for a New England Patriots-style comeback. Bob Pisani at CNN says there are reasons to be optimistic. Leading… Read more »
